Side effects of reirradiation with concurrent chemotherapy inrecurrent head and neck cancer patients
DOI:
https://doi.org/10.55312/op.vi2.4523Abstract
From 2012-2015 are retreated twenty head and neck cancer patients with unresectable recurrences after a fi rst treatment with surgery and/or radiochemotherapy. There were 16 men and 4 women with a median age of 58 years (47-75years). Patients had a Karnofsky Performance State of 60-80%. All patients were treated with 3Dimensionalhyperfractionated radiotherapy concurrent with weekly Cisplatin 40mg/m².Median interval between the fi rst and second radiotherapy treatment was 25 months (12-59months). Radiotherapy dose of the fi rst treatment ranged between 50-66Gy,and of reirradiation between 30-40 Gy. During retreatment and follow up all side eff ects were evaluated.Keywords:
side eff ects, reirradiation, chemotherapy, head and neck cancer.Downloads
References
-
Vermorker JB, Specenier P. Optimal treatment for recurre nt/ metastatic head and neck cancer. Ann Oncol 2010; 20:252–61.
-
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior defi nitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011;
-
:1292–8.
-
Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1995; 32:605–9.
-
Teman S, Pape E, Janot F, Wibault P, Julieron M, Lusinchi A, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:1078–83.
-
Hoebers F, Heemsbergen W, Moor S, Lopez M, Klop M, Tesselaar M, et al. Reirradiation for head-and-neck cancer: delicate balance between eff ectiveness and toxicity. Int J Radiat Oncol Biol Phys 2011; 81:111–8.
-
Ang KK, Price RE, Stephens LC, et al. The tolerance of primate spinal cord to reirradiation. Int J Radiat Oncol BiolPhys 1993; 25:459–464.
-
Hornsey S, Myers R, Warren P. Residual injury in the spinal cord after treatment with X-rays or neutrons. Br J Radiol 1982; 55:516 –519.
-
Lee AWM, Foo W, Law SCK, et al. Reirradiation for recurrent nasopharyngeal carcinoma: Factors aff ecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 1997; 38:43–52.
-
Janssen S, Baumgartner M, Bremer M, Warszawski A, Stieve M, Eckarrdt A, et al. Re-irradiation of head and neck cancer – impact of total dose on outcome. Anticancer Res 2010; 30:3781–6.
-
Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multiinstitutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 20:281–8.
-
Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course
-
concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. J Clin On col.
-
Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defi ning the targets. Int J Radiat Oncol Biol Phys. 2009; 74:1342–7.
-
Vargo JA, Ferris RL, Ohr J, et al. Aprospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015; 91:480–8.
References
Vermorker JB, Specenier P. Optimal treatment for recurre nt/ metastatic head and neck cancer. Ann Oncol 2010; 20:252–61.
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior defi nitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011;
:1292–8.
Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1995; 32:605–9.
Teman S, Pape E, Janot F, Wibault P, Julieron M, Lusinchi A, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:1078–83.
Hoebers F, Heemsbergen W, Moor S, Lopez M, Klop M, Tesselaar M, et al. Reirradiation for head-and-neck cancer: delicate balance between eff ectiveness and toxicity. Int J Radiat Oncol Biol Phys 2011; 81:111–8.
Ang KK, Price RE, Stephens LC, et al. The tolerance of primate spinal cord to reirradiation. Int J Radiat Oncol BiolPhys 1993; 25:459–464.
Hornsey S, Myers R, Warren P. Residual injury in the spinal cord after treatment with X-rays or neutrons. Br J Radiol 1982; 55:516 –519.
Lee AWM, Foo W, Law SCK, et al. Reirradiation for recurrent nasopharyngeal carcinoma: Factors aff ecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 1997; 38:43–52.
Janssen S, Baumgartner M, Bremer M, Warszawski A, Stieve M, Eckarrdt A, et al. Re-irradiation of head and neck cancer – impact of total dose on outcome. Anticancer Res 2010; 30:3781–6.
Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multiinstitutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 20:281–8.
Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course
concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. J Clin On col.
Popovtzer A, Gluck I, Chepeha DB, Teknos TN, Moyer JS, Prince ME, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defi ning the targets. Int J Radiat Oncol Biol Phys. 2009; 74:1342–7.
Vargo JA, Ferris RL, Ohr J, et al. Aprospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015; 91:480–8.
Shqip
English
Italiano
